2021年最新SCI期刊影响因子查询系统
Therapeutic Advances in Medical Oncology 期刊详细信息
基本信息
期刊名称 | Therapeutic Advances in Medical Oncology Therapeutic Advances in Medical Oncology |
---|---|
期刊ISSN | 1758-8340 |
期刊官方网站 | http://tam.sagepub.com/ |
是否OA | 是 |
出版商 | SAGE Publications Inc. |
出版周期 | |
始发年份 | |
年文章数 | 67 |
最新影响因子 | 5.485(2021) |
中科院SCI期刊分区
大类学科 | 小类学科 | Top | 综述 |
---|---|---|---|
医学2区 | ONCOLOGY 肿瘤学2区 | 否 | 是 |
CiteScore
CiteScore排名 | CiteScore | SJR | SNIP | ||
---|---|---|---|---|---|
学科 | 排名 | 百分位 | 5.44 | 2.200 | 1.659 |
Medicine Oncology |
33 / 321 | 89% |
补充信息
自引率 | 1.20% |
---|---|
H-index | 24 |
SCI收录状况 |
Science Citation Index Expanded |
官方审稿时间 | |
网友分享审稿时间 | 数据统计中,敬请期待。 |
PubMed Central (PML) | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1758-8340%5BISSN%5D |
投稿指南
期刊投稿网址 | https://us.sagepub.com/en-us/nam/journal/therapeutic-advances-medical-oncology#submission-guidelines |
---|---|
收稿范围 | Therapeutic Advances in Medical Oncology delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in medical oncology, providing an online forum for rapid dissemination of recent research and perspectives in this area. The editors welcome original research articles across all areas of oncology. The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies – all phases. Letters to the Editor and Case Reports will also be considered. Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). The journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable. The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees; a first editorial decision is generally reached within 3 weeks of submission and Online First publication is usually within 3 weeks of Acceptance. |
收录体裁 | |
投稿指南 | |
投稿模板 | |
参考文献格式 | |
编辑信息 |